ENDRA Life Sciences Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

NDRA$4.77-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

24.1 Power of Attorney (included on signature page)

POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of ENDRA Life Sciences Inc., hereby severally constitute and appoint Francois Michelon our true and lawful attorney, with full power to him to sign for us and in our names in the capacities indicated below, any amendments to this Annual Report on Form 10-K, and generally to do all things in our names and on our behalf in such capacities to enable ENDRA Life Sciences Inc. to comply with the provisions of the Securities Exchange Act of 1934, as amended, and all the requirements of the Securities Exchange Commission.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Francois Michelon
Signatures	Title	Date
/s/ Francois Michelon	Chief Executive Officer and Director (Principal Executive Officer)	March 28, 2024
/s/ Irina Pestrikova	Senior Director, Finance (Principal Financial and Accounting Officer)	March 28, 2024
Irina Pestrikova
/s/ Louis J. Basenese	Director	March 28, 2024
Louis J. Basenese
/s/ Anthony DiGiandomenico	Director	March 28, 2024
Anthony DiGiandomenico
/s/ Michael Harsh	Director	March 28, 2024
Michael Harsh
/s/ Alexander Tokman	Director	March 28, 2024
Alexander Tokman

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.